Best of ASCO - 2014 Annual Meeting

 

Welcome

Attend this session at the
2019 ASCO Annual Meeting!


Session: Gastrointestinal (Colorectal) Cancer

Type: Poster Session

Time: Monday June 3, 8:00 AM to 11:00 AM

Location: Hall A


Session: Gastrointestinal (Colorectal) Cancer

Type: Poster Discussion Session

Time: Monday June 3, 11:30 AM to 1:00 PM

Location: Arie Crown Theater

Long-term survival after laparoscopic versus open resection for colorectal liver metastases.

Sub-category:
Advanced Disease

Category:
Gastrointestinal (Colorectal) Cancer

Meeting:
2019 ASCO Annual Meeting

Abstract No:
LBA3516

Poster Board Number:
Poster Discussion Session (Board #8)

Citation:
J Clin Oncol 37, 2019 (suppl; abstr LBA3516)

Author(s): Åsmund Avdem Fretland, Davit Aghayan, Bjørn Edwin, OSLO-COMET Trial Group; Oslo University Hospital, Oslo, Norway

Abstract Disclosures

Abstract:

Background: Despite the recent worldwide dissemination of laparoscopic liver surgery, the long-term oncologic outcomes of laparoscopic and open liver surgery have never been compared in a randomized controlled trial. Methods: OSLO-COMET was a randomized controlled trial recruiting patients from Oslo University Hospital, Oslo, Norway. The primary outcome of the trial was postoperative morbidity within 30 days. Patients with radically resectable liver metastases from colorectal cancer were randomly assigned to undergo laparoscopic or open parenchyma-sparing liver resection. Overall survival was a predefined secondary endpoint for the trial. Survival data for the treatment arms will be compared using a log-rank test and Kaplan-Meier plots. Results: From February 2012 to January 2016 a total of 294 patients were screened and 280 (95%) patients were randomized to laparoscopic (n = 133) or open (n = 147) surgery. The primary endpoint demonstrated a significant reduction in morbidity from 31% in the open group to 19% in the laparoscopic group. Other secondary outcomes demonstrated no difference between the groups, including the rate of R0 resection and the width of resection margins, while laparoscopic surgery was found to be cost-effective. Patients received perioperative chemotherapy following Norwegian guidelines. The final patient was operated on Feb 28, 2016, and a survival analysis was performed on March 14, 2019, with a minimum of 36 months follow-up. By ITT analysis (n = 280), median overall survival (OS) was 80 months (95% CI 52-108) in the laparoscopic surgery group and 81 months (95% CI 42-120) in the open surgery group, p=0.91. By modified ITT, (only patients that had R0/R1 resection), median recurrence free survival (RFS) was 19 months (10-27) in the laparoscopic group and 16 months (11-21) in the open group, p = 0.96. Conclusions: Laparoscopic surgery in patients with colorectal liver metastases was associated with rates of OS and RFS similar to open surgery. Clinical trial information: NCT01516710

 
Other Abstracts in this Sub-Category:

 

1. Randomized phase III study comparing FOLFOX + bevacizumab versus folfoxiri + bevacizumab (BEV) as 1st line treatment in patients with metastatic colorectal cancer (mCRC) with ≥3 baseline circulating tumor cells (bCTCs).

Meeting: 2019 ASCO Annual Meeting Abstract No: 3507 First Author: Javier Sastre
Category: Gastrointestinal (Colorectal) Cancer - Advanced Disease

 

2. Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the first- and second-line treatment of unresectable mCRC.

Meeting: 2019 ASCO Annual Meeting Abstract No: 3508 First Author: Chiara Cremolini
Category: Gastrointestinal (Colorectal) Cancer - Advanced Disease

 

3. A randomized phase II trial of second-line CAPTEM versus FOLFIRI in MGMT methylated, RAS mutated metastatic colorectal cancer (mCRC) patients.

Meeting: 2019 ASCO Annual Meeting Abstract No: 3509 First Author: Filippo Pietrantonio
Category: Gastrointestinal (Colorectal) Cancer - Advanced Disease

 

More...